A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)
A Phase 2, Randomized, Observer-blind, Dose-finding, Placebo-controlled Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982, an mRNA Vaccine to Prevent Lyme Disease in Healthy Adult Participants (18 to 70 Years of Age)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Moderna WeCare Team
- Phone Number: 1-866-663-3762
- Email: WeCareClinicalTrials@modernatx.com
Study Locations
-
-
-
Québec, Canada, G1V 4T3
- Diex Recherche Inc. - Division Quebec
-
-
Nova Scotia
-
Truro, Nova Scotia, Canada, B2N 1L2
- Colchester Research Group
-
-
Ontario
-
Sarnia, Ontario, Canada, N7T 4X3
- Bluewater Clinical Research Group Inc.
-
Stouffville, Ontario, Canada, L4A 1H2
- Stouffville Medical Research Institute Inc.
-
Toronto, Ontario, Canada, M9V 4B4
- Dr. Anil K. Gupta Medicine Professional Corporation Inc.
-
-
Quebec
-
Joliette, Quebec, Canada, J6E 6A9
- Diex Recherche Inc. - Division Joliette
-
Sherbrooke, Quebec, Canada, J1L 0H8
- Diex Recherche Inc. - Division Sherbrooke
-
Victoriaville, Quebec, Canada, G6P 3Z8
- Diex Recherche Inc. - Division Victoriaville
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- In good general health in the opinion of the investigator as determined by medical evaluation including medical history and physical examination at screening.
- Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Key Exclusion Criteria:
- History of anaphylaxis or severe hypersensitivity reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic or any components of an mRNA vaccine or therapeutic.
- Have chronic illness related to Lyme disease or an active symptomatic Lyme disease infection as suspected or diagnosed by a physician.
- Received treatment for Lyme disease within the prior 3 months.
- Previously vaccinated against Lyme disease or participated in the past in any vaccine study for Lyme disease.
- Had a tick bite within 4 weeks prior to Day 1.
Note: Additional inclusion/exclusion criteria may apply, per protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dose-finding Phase
Participants will receive mRNA-1982 or placebo as an intramuscular injection.
|
Suspension for injection
Suspension for injection
|
|
Experimental: Booster Phase
Participants will receive mRNA-1982 (as a booster) or placebo as an intramuscular injection.
|
Suspension for injection
Suspension for injection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Both Phases: Number of Participants with Solicited Local and Systemic Adverse Reactions
Time Frame: Day 1 up to Day 7 (7 days post-injection)
|
Day 1 up to Day 7 (7 days post-injection)
|
|
Both Phases: Number of Participants with Unsolicited Adverse Events
Time Frame: Day 1 up to Day 28 (28 days post-injection)
|
Day 1 up to Day 28 (28 days post-injection)
|
|
Both Phases: Number of Participants with Medically Attended Adverse Events, Adverse Events of Special Interest, Serious Adverse Events, and Adverse Events Leading to Discontinuation
Time Frame: Day 1 up to Month 21 (End of study)
|
Day 1 up to Month 21 (End of study)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Dose-finding Phase: Geometric Mean Concentration (GMC) of Anti-outer Surface Protein A (OspA) Serotype 1 (ST1) Binding Immunoglobulin G (IgG) Antibodies (Ab)
Time Frame: Days 1, 113, 197, 265, and 349
|
Days 1, 113, 197, 265, and 349
|
|
Dose-finding Phase: Geometric Mean Fold Rise (GMFR) of Anti-OspA ST1 Binding IgG Ab
Time Frame: Days 113, 197, 265, and 349
|
Days 113, 197, 265, and 349
|
|
Booster Phase: GMC of Anti-OspA ST1 Binding IgG Ab
Time Frame: Days 1, 29, and 181 of Booster Phase
|
Days 1, 29, and 181 of Booster Phase
|
|
Booster Phase: GMFR of Anti-OspA ST1 Binding IgG Ab
Time Frame: Days 29 and 181 of Booster Phase
|
Days 29 and 181 of Booster Phase
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- mRNA-1982-P201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.